Pan-Canadian Pharmaceutical Alliance

What Pan-Canadian Pharmaceutical Alliance does

The Pan-Canadian Pharmaceutical Alliance (pCPA) is a federal-provincial-territorial coordination body that negotiates drug prices with pharmaceutical manufacturers on behalf of all Canadian federal, provincial, and territorial public drug plans. Headquartered virtually with a team of 11-50 located across Canada, pCPA operates as a multilateral negotiating entity rather than a commercial enterprise: it generates no revenue, and its mission is to deliver cost savings and consistent coverage to publicly funded drug benefit programs. As of the latest disclosed data, the organization has concluded 790 negotiations and achieved $3.94 billion in cumulative brand-name drug savings and $935 million in generic drug savings, with prices and outcomes kept confidential between pCPA and manufacturers.

pCPA's core "products" are structured negotiation process frameworks, including standard, expedited, early, targeted, and temporary access processes, applied across three drug categories: brand-name, generic, and biosimilar. Supporting frameworks include a Tiered Pricing Framework, a Centralized Price Change Process, and a public-facing Performance Dashboard that publishes negotiation outcomes, timelines, and savings metrics. Its go-to-market is enterprise field-sales equivalent: pCPA engages pharmaceutical manufacturers directly in formal negotiations, after which individual public drug plans adopt the agreed terms and list covered drugs on their formularies. The organization works sequentially with Canada's Drug Agency, whose reviews average 7.9 months, followed by pCPA price negotiations averaging 8.1 months.

pCPA is funded through participating public drug plans, has no private ownership or external capital, and operates under a collaborative governance structure. Notable recent activity includes a 2025 Letter of Intent with CSL Behring for HEMGENIX gene therapy reimbursement (October 2025), a concluded Cosentyx reimbursement agreement with Novartis (July 2025), an extension of the generic drug pricing agreement with the Canadian Generic Pharmaceutical Association through 2028, and the release of the 2026-2029 Strategic Plan "Driving Change, Delivering Impact." pCPA is led by CEO Douglas Clark.

Name

Pan-Canadian Pharmaceutical Alliance

Legal name

pan-Canadian Pharmaceutical Alliance

Website

https://pcpacanada.ca

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

The Pan-Canadian Pharmaceutical Alliance (pCPA) is a Canadian federal-provincial-territorial body that negotiates drug prices with manufacturers on behalf of all public drug plans. It has concluded 790 negotiations, delivering $3.94B in brand-name and $935M in generic drug savings.

Ownership category

akta.pro rank

Product category

Pharmaceutical Price Negotiation Services

NAICS

Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)

akta.pro primary industry

Public–Private Partnerships (PPPs) for Global Health (HLAJAOAD)

Keywords

• Drug price negotiation
• Public drug reimbursement
• Pharmaceutical pricing agreements
• Public formulary management
• Biosimilar drug negotiations

Headquarters

HQ city

Ottawa

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Public drug plan cost reduction: pCPA does not generate revenue. It operates as a collective negotiating body that reduces costs for publicly funded drug plans by negotiating drug prices with pharmaceutical manufacturers on behalf of Canadian federal, provincial, and territorial governments. The organization generates cost savings rather than revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

The Pan-Canadian Pharmaceutical Alliance (pCPA) is a collective negotiating body that conducts price negotiations with pharmaceutical manufacturers on behalf of all Canadian federal, provincial, and territorial public drug plans. It negotiates prices for brand-name, generic, and biosimilar drugs using structured processes including standard, expedited, early, targeted, and temporary access pathways, enabling public drug plans to list covered medications at agreed-upon prices.

Product overview

The pan-Canadian Pharmaceutical Alliance (pCPA) is a coordination body that negotiates drug prices with pharmaceutical manufacturers on behalf of federal, provincial, and territorial public drug plans. Rather than a single product, the pCPA offers a portfolio of negotiation process frameworks including Standard Negotiation, Expedited Pathways, Early Negotiation, Targeted Negotiation, and Temporary Access processes. The organization categorizes its work into three drug types: brand-name drugs, generic drugs, and biosimilar drugs. Supporting services include a Tiered Pricing Framework, Centralized Price Change Process, and a Performance Dashboard for tracking negotiation outcomes and savings. As of the available data, the pCPA has achieved $3.94 billion in total savings for brand-name drugs, $935 million for generic drugs, and 790 negotiations ended with agreements.

Differentiator

Problem solved

Functional benefit

Products and services

• Brand-name Drug Negotiation Services

Quantifiable outcome

• $3.94B total savings for brand-name drugs through collective negotiations
• +3 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core, major and minor.

• Canadian Generic Pharmaceutical Association (CGPA)coreStrategic or Co-development Partner · 1 February 2026pCPA and CGPA extended their agreement on pricing initiative for generic drugs to 2028, contributing to $935M in total generic drug savings. This partnership framework governs pricing negotiations for generic pharmaceuticals across Canadian public drug plans.
• CSL BehringmajorStrategic or Co-development Partner · 9 October 2025CSL Behring signed a Letter of Intent with pCPA for public reimbursement of HEMGENIX (etranacogene dezaparvovec), the first gene therapy for hemophilia B. This agreement enables provinces outside Quebec to list the therapy, with ongoing discussions in Quebec for reimbursement.
• Novartis Pharmaceuticals Canada Inc.majorStrategic or Co-development Partner · 11 July 2025Novartis successfully concluded negotiations with pCPA for public reimbursement of Cosentyx (secukinumab) for adults with moderate to severe hidradenitis suppurativa (HS). Quebec became the first province to list Cosentyx for HS, marking a milestone toward broader public access across Canada.
• Canada's Drug AgencycoreStrategic or Co-development PartnerpCPA works with Canada's Drug Agency in the sequential drug approval and reimbursement process. Canada's Drug Agency conducts initial reviews (averaging 7.9 months) before pCPA negotiates pricing (averaging 8.1 months), then individual public plans finalize coverage.
• Novo NordiskminorStrategic or Co-development PartnerCanadian public health plans ended negotiations with Novo Nordisk regarding coverage for the weight-loss drug Wegovy. This reflects ongoing policy and healthcare coverage discussions in Canada regarding high-cost specialty medications.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• NICE (National Institute for Health and Care Excellence): UK's health technology assessment body that evaluates cost-effectiveness and makes reimbursement recommendations to NHS England. Operates as a centralized public payer assessment and pricing function, structurally analogous to pCPA's role for Canadian public drug plans.
• PHARMAC (New Zealand): New Zealand's national pharmaceutical purchasing agency that negotiates drug prices on behalf of public health system. PHARMAC is widely regarded as one of the most centralized and aggressive public drug price negotiators, making it the closest international functional analog to pCPA.
• CEPS (Comité Économique des Produits de Santé): France's national drug pricing committee that negotiates drug prices with manufacturers on behalf of the French national health insurance system. Performs an almost identical collective negotiating role to pCPA within the French statutory health insurance framework.
• PBAC (Pharmaceutical Benefits Advisory Committee): Australia's independent expert body that recommends which medicines should be listed on the Pharmaceutical Benefits Scheme (PBS). Combined with the PBS negotiation function, PBAC serves as Australia's structural equivalent of pCPA in assessing and pricing drugs for public reimbursement.
• G-BA (Gemeinsamer Bundesausschuss): Germany's federal joint committee that decides which services and drugs are reimbursed by statutory health insurance. G-BA's benefit assessment and price negotiation functions parallel pCPA's pricing negotiations for Canadian public drug plans.
• TLV (Dental and Pharmaceutical Benefits Agency): Sweden's central government agency that determines whether a pharmaceutical product shall be subsidized and at what price. TLV operates a value-based pricing model analogous to pCPA's tiered and negotiation-based pricing approach for Swedish public reimbursement.
• ZIN (Zorginstituut Nederland): Dutch national health care institute that advises on and manages the reimbursement of pharmaceuticals in the Netherlands. Performs package management and price negotiation functions that closely mirror pCPA's role in Canada's public drug plan system.
• AIFA (Agenzia Italiana del Farmaco): Italy's national pharmaceutical agency responsible for drug pricing and reimbursement decisions within the Italian national health service. AIFA's pricing and reimbursement negotiation role is structurally equivalent to pCPA's collective negotiation function.

Regional players

• CVZ / NZa (Netherlands Healthcare Authority): Dutch healthcare market regulator with overlapping drug pricing oversight responsibilities. While regional, its pricing and reimbursement oversight provides a comparative European benchmark for assessing pCPA's negotiation outcomes and processes.

Others

• Canada's Drug Agency (CDA-AMC): Sequential upstream partner that conducts health technology assessments and reimbursement reviews before pCPA negotiations begin. Functions as pCPA's immediate pipeline feeder and is critical to the end-to-end Canadian public reimbursement system.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pan-canadian-pharmaceutical-alliance

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pan-Canadian Pharmaceutical Alliance